SHIFT Newsroom · GLOBAL
Semaglutide Investigated for Alcohol Use Disorder After Metabolic and Bariatric Surgery
A clinical trial is exploring the use of Semaglutide for Alcohol Use Disorder in patients who have undergone Metabolic and Bariatric Surgery
A clinical trial has been registered to investigate the use of Semaglutide for Alcohol Use Disorder in patients who have undergone Metabolic and Bariatric Surgery. The trial is currently recruiting participants and aims to provide insight into the efficacy of Semaglutide for this indication.
What this means in the UK
This trial may provide insight into a potential new treatment option for individuals in the UK who struggle with Alcohol Use Disorder after undergoing Metabolic and Bariatric Surgery
Known facts
- Semaglutide is being investigated for Alcohol Use Disorder after Metabolic and Bariatric Surgery